epigenetics Archives

cellular reprogramming with Shift Bioscience

News and Trends 21 Oct 2024

Turning back time with cellular reprogramming: Shift raises $16 million in seed funding

As Shift Bioscience raises $16 million in seed funding, delve into the field of cellular reprogramming to tackle age-related diseases.

October 21, 2024 - 9 minutesmins - By Jules Adam

Best in Biotech 2 Aug 2024

Six epigenetics companies making strides in 2024

In this article, we take a look at six epigenetics companies that are significant as well as up-and-coming players in the industry.

August 2, 2024 - 7 minutesmins - By Roohi Mariam Peter

Podcast 19 Jan 2024

Epigenetic editing – the power of CRISPR without cutting DNA

Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells. This enables in vivo or ex vivo delivery via a single viral vector. Epic’s lead program, EPI-321, is in IND-enabling studies […]

January 19, 2024

Best in Biotech 26 Sep 2023

Eight anti-aging startups on a mission to extend lives

The longevity biotech industry revolves around the goal of increasing the period of life that a person spends in good health. There has been a rapidly expanding effort in recent years to develop drugs that target aging as a root cause of disease, and this type of biotechnology has come to be a very popular […]

September 26, 2023 - 10 minutesmins - By Willow Shah-Neville

News and Trends 10 May 2023

Cell rejuvenation for age-related diseases

By Sharon Rosenzweig-Lipson, CSO, Life Biosciences Cellular rejuvenation is quickly becoming a hot topic in the development of novel therapeutic modalities for a range of diseases. The leading approaches to cellular rejuvenation currently in development utilize epigenetic reprogramming to achieve this goal. Epigenetics is the study of how positive and negative lifestyle factors (exercise, smoking, […]

May 10, 2023 - 3 minutesmins - By External Contributor

News and Trends 14 Apr 2023

biomodal launches new multiomics sequencing technology

biomodal, formerly known as Cambridge Epigenetix, has launched its new duet multiomics solution, which it says reveals the combinatorial power of genetic and epigenetic information from a single low volume sample. The duet multiomics solution is the world’s first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a […]

April 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Genomic medicine company Chroma raises $135M

Chroma Medicine, Inc., a genomic medicine company advancing single-dose epigenetic editing therapeutics, has completed a $135 million Series B financing. The funding was led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, […]

March 2, 2023 - 2 minutesmins - By Jim Cornall

More News! 28 Oct 2022

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

A whole new level of control of cancer gene activity within tumors, has been described by researchers as ‘dark matter’. It was recently discovered and published in two major studies at the same time in Nature that cancers can evolve to become more aggressive without relying on DNA mutations. Testing cancers for just the DNA […]

October 28, 2022 - 6 minutesmins - By Liza Laws

News and Trends 25 Jun 2018

Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers

Update (25/06/2018): Oryzon enrolls first patients in the UK in its clinical trial testing its epigenetic Alzheimer’s drug. The company plans to enroll a total of 90 patients in Spain, France and the UK. Update (14/05/2018): Oryzon has been given approval to expand to France its Phase IIa clinical trial for an epigenetic Alzheimer’s drug. The […]

June 25, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 May 2018

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […]

May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2017

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may have stumbled across a new approach for its treatment. Researchers at the Medical University of Vienna have identified a target for the treatment of multiple sclerosis (MS). The research, published in the Journal of Autoimmunity, found that histone deacetylases (HDACs) play […]

October 19, 2017 - 3 minutesmins - By Alex Dale

News and Trends 13 Sep 2017

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

epigenetics

Turning back time with cellular reprogramming: Shift raises $16 million in seed funding

Six epigenetics companies making strides in 2024

Epigenetic editing – the power of CRISPR without cutting DNA

Eight anti-aging startups on a mission to extend lives

Cell rejuvenation for age-related diseases

biomodal launches new multiomics sequencing technology

Genomic medicine company Chroma raises $135M

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!